Lysosomal and Rare Disorders Research and Treatment Center, Inc.
9
1
1
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Biomarkers Related to Bone in Pediatric Gaucher Disease
Role: lead
The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)
Role: lead
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
Role: lead
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy
Role: lead
Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease
Role: lead
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease
Role: lead
Biomarker Analysis for GBA Associated Parkinson's Disease
Role: lead
Screening of Lysosomal Storage Disorders Diseases in Minority Groups
Role: lead
Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders
Role: lead
All 9 trials loaded